Zoeken

Fewer breast and colorectal cancer diagnoses due to the COVID-19 crisis in the Netherlands Fewer breast and colorectal cancer diagnoses have been made in the Netherlands due to the COVID-19 crisis this spring. The decline in the number of diagnoses was more abundant in age groups invited to national population screening programmes, as compared to other age groups. More specifically, there was a drop of approximately one-third in breast cancer diagnoses (including its precursor) among 50-74-year-old women and approximately one-fifth in colorectal cancer diagnoses among 55-75-year-old men and women. These are the age groups that are invited to national population screening programmes in the Netherlands. Avinash Dinmohamed, Sabine Siesling, and coauthors described these findings in the Journal of Hematology & Oncology based on data from the Netherlands Cancer Registry (NCR) that relies on pathological cancer notifications via the Nationwide Histopathology and Cytopathology Data Network and Archive (PALGA). iknl.nl/en/news/fewer-breast-and-colorectal-cancer-diagnoses-due-t Laatst gewijzigd op: 6 november 2020

Breast cancer follow-up can be less intensive, tailored to individual risk Doctoral research by Annemieke Witteveen at the University of Twente has shown that the number of follow-up visits for women after breast cancer treatment in the Netherlands could be reduced by about 9,000 visits per year. The follow-up could be offered based on the to the risk of recurrence, so that women with a low risk possible would need to revisit the hospital for a mammogram less frequently. Personalized follow-up reduces the burden on patients, care providers and possible the care budget. iknl.nl/en/news/breast-cancer-follow-up-can-be-less-intensive Laatst gewijzigd op: 18 november 2018

English translation Dutch Cancer Atlas available With the launch of the Dutch Cancer Atlas by the Netherlands Comprehensive Cancer Organisation (IKNL) in January 2023, anyone can gain insight into the regional impact of cancer in the Netherlands. Now, the Dutch Cancer Atlas is also available in English; you can switch to English by clicking on the ‘change language’ button (with the flag) within the atlas itself. The interactive online atlas shows geographical patterns in cancer diagnoses, based on where people lived when they were diagnosed. IKNL analyzed these patterns for the 24 most common cancers in the Netherlands and for all of those cancers combined. Geographical variation can be observed for certain cancers, while for others, there is little to no variation. For all cancers combined, there is minimal geographical variation in the Netherlands. iknl.nl/en/news/english-translation-dutch-cancer-atlas-available

IKNL launches renewed international website IKNL (Netherlands Comprehensive Cancer Organisation) has launched its renewed international website: iknl.org. The website is designed to better inform international partners, researchers and policymakers about IKNL’s work, the Netherlands Cancer Registry (NCR), and scientific collaborations in the field of cancer. iknl.nl/en/news/iknl-international Laatst gewijzigd op: 9 april 2025

European collaboration in FLORENCE project Using AI to improve treatment of patients with colorectal cancer One in four patients in Denmark experience complications after colon cancer surgery, leading to re-admission, permanent damage and, in some cases, early death. A new research project, called FLORENCE, aims to improve the diagnosis, prognosis and treatment of patients with colon cancer. The project will develop an artificial intelligence (AI) tool to give doctors a better basis for decisions on patient treatment. iknl.nl/en/news/florence Laatst gewijzigd op: 22 juni 2023

Changes to primary endpoints in immunotherapy trials: common and untransparent Nearly two-thirds of 38 examined randomized trials of immunotherapy in bladder, lung and kidney cancer included adjustment to primary endpoints. Only a minority of these studies reported these changes transparently, contrary to current guidelines. These are the outcomes of a review published by the Netherlands Comprehensive Cancer Organisation (IKNL), Radboud University Medical Center (The Netherlands), and Queens University Cancer Research Institute (Canada). iknl.nl/en/news/changes-primary-endpoints-trials Laatst gewijzigd op: 21 juni 2023

ALERTNESS; structural signaling for up-to-date guidelines With financial support of ZonMw, IKNL partnered with the Dutch Association of Obstetrics and Gynecology (NVOG), Olijf Foundation and National Comprehensive Cancer Network® (NCCN®) to start the project ALERTNESS. The aim of the ALERTNESS project is to identify new developments in science and clinical practice to support timely guideline revision. Endometrial (uterine) cancer is the most common gynecological cancer in Western countries. In the Netherlands, about 1,900 new cases are diagnosed every year. All women with endometrial cancer are discussed in a multidisciplinary meeting and, if necessary, sent to one of the eight gynecological-oncology centers in their region. For optimal quality of care, it is important to treat these women according to the latest insights. Partly because several successive (gynecological) care providers are involved, an up-to-date and accessible guideline is crucial to ensure that every patient receives the right care in the right place. iknl.nl/en/guidelines/alertness;-structural-signaling-for-up-to-date-gui Laatst gewijzigd op: 8 september 2022

LANCELOT: new collaboration between IKNL and TNO to enable privacy preserving analyses on cancer-related data. The LANCELOT project is part of an ongoing strategic collaboration between the Netherlands Comprehensive Cancer Organisation (IKNL) and TNO, together with Janssen Pharmaceutica NV, to develop data infrastructure and AI solutions to enable the use of sensitive health data. LANCELOT will help to reduce the impact of cancer while preserving patients’ privacy. LANCELOT focuses on problems where the data of patients are spread across different organizations, for example at the General Practitioner, the hospital and the pharmacy databases. We are looking for additional partners in healthcare, to bring our solutions to the next level by performing pilot studies, embedding the solutions within legal agreements, and using data in a privacy-preserving manner. iknl.nl/en/news/lancelot-new-collaboration-between-iknl-and-tno-to Laatst gewijzigd op: 19 november 2021

Cancer diagnoses in the Netherlands rising to 156,000 a year in the next decade The number of new cancer diagnoses in the Netherlands is to rise considerably to 156,000 diagnoses a year in the next ten years, due to the ageing population and lifestyle. This increase in the coming ten years is largely inevitable, but commitment to preventative measures now is necessary to prevent a further increase in the number of cancer diagnoses in the more distant future. This is shown in the trend report ‘Kanker in Nederland - trends & prognoses tot en met 2032’ (Cancer in the Netherlands - trends and prognoses until 2032) that the Netherlands Comprehensive Cancer Organisation (IKNL) published on the 4th of October. iknl.nl/en/news/cancer-diagnoses-in-netherlands-rising Laatst gewijzigd op: 24 oktober 2022

Cancer registries as fuel and engine for data driven rapid learning health systems, an interview with dr. Xander Verbeek In the Dutch session at HIMSS2021 dr. Xander Verbeek, head Research & Development at the Netherlands Comprehensive Cancer Organization was invited to share his vision on data analytics in oncology. He emphasized the role of the cancer registrations as fuel and engine for data driven rapid health systems, with the overall aim to learn from patients and improve health care. What is his vision for the future of data and AI to improve quality of cancer care? iknl.nl/en/news/cancer-registries-as-fuel-and-engine-for-data-driv Laatst gewijzigd op: 31 mei 2021

Zoekresultaten